

Sector: Agri Chem  
Result Update

	Change
Reco: <b>Buy</b>	↑
CMP: <b>Rs. 1,547</b>	
Price Target: <b>Rs. 1,750</b>	↑

↑ Upgrade   ↔ No change   ↓ Downgrade


## Company details

Market cap:	Rs. 21,363 cr
52-week high/low:	Rs. 1,626/864
NSE volume: (No of shares)	1.4 lakh
BSE code:	523642
NSE code:	PIIND
Sharekhan code:	PIIND
Free float: (No of shares)	6.7 cr

## Shareholding (%)

Promoters	51
FII	14
DII	21
Others	14

## Price chart



## Price performance

(%)	1m	3m	6m	12m
Absolute	8.8	10.1	38.6	76.3
Relative to Sensex	8.9	6.8	25.1	51.7

Sharekhan Research, Bloomberg

PI Industries Limited (PI Industries) delivered revenue growth of 20.1% y-o-y to Rs. 850 crore during Q3FY2020, led by robust revenue growth of 24% y-o-y in domestic business and continued ramp-up in exports (up by 19% y-o-y). Gross margin remained at similar levels of 46.6%, however operating margins improved by 94 BPS y-o-y to 21.9% owing to economies of scale as other operating cost was down by 96 BPS to 15.7% of sales as compared to 16.6% during Q3FY2019. Healthy revenue growth and improvement in operating margin led to 25.5% growth in EBITDA at Rs. 187 crore. However, increased depreciation (up by 36.3% y-o-y) restricted PBT growth in PBT to 22.3% despite other income being higher by 25.7% y-o-y. Higher tax incidence of 28.7% in Q3FY2020 as against 22.8% in Q3FY2019 further restricted growth in PAT to 13.0% to Rs. 121 crore. Management has retained its FY2020E guidance of ~20% y-o-y improvement in performance, led by healthy order book, commissioning of additional capacity and contribution from newly launched brands. The Board has also approved an enabling resolution to raise funds upto Rs. 2,000 crore so as to support the next phase of growth.

## Key positives

- Robust revenue growth of 24% y-o-y in domestic business (largely volume driven) and continued ramp-up in exports (up by 19% y-o-y).
- OPM expanded by 94 BPS to 21.9%, led by economies of scale and cost efficiencies.

## Key negatives

- Export order book remained flat at US\$ 1.4 billion.

## Our Call

**Valuation: Aggressive expansion strategy to tap the robust and encouraging demand environment – Upgrade to Buy:** We expect revenue and earnings CAGR of 27.6% and 29.8%, respectively, during FY2019-FY2022E (Isagro numbers factored in from Q4FY2020). At the current market price, the stock is trading at 40.2x/28.9x/23.8x its FY2020E/FY2021E/FY2022E earnings. With industry-leading return ratios, healthy balance sheet and strong earnings visibility; we expect the stock to continue to fetch premium valuations. We upgrade our rating on the stock to Buy with a revised PT of Rs. 1,750 per share owing to aggressive expansion strategy to tap the robust and encouraging demand environment.

## Key Risks

- Delay in commissioning of projects or execution of orders or delayed orders by clients in the CSM business can affect revenue growth.
- Higher-than-normal time lag in passing on the increase in raw-material prices could affect margins.

## Valuation (consolidated)

	Rs cr				
Particulars	FY18	FY19	FY20E	FY21E	FY22E
Revenues	2,277	2,841	3,528	4,844	5,902
OPM (%)	21.7	20.3	21.2	21.5	21.7
Adjusted PAT	368	410	529	737	896
% y-o-y growth	(20.0)	11.5	29.1	39.4	21.5
Adjusted EPS (Rs.)	26.7	29.8	38.5	53.6	65.1
P/E (x)	57.9	51.9	40.2	28.9	23.8
P/B (x)	11.1	9.3	7.7	6.2	5.0
EV/EBITDA (x)	42.6	36.6	28.3	20.2	16.2
RoNW (%)	20.7	19.5	21.0	23.8	23.2
RoCE (%)	25.0	24.9	27.1	30.7	29.9

Source: Company; Sharekhan estimates

**Healthy performance continues:** PI Industries delivered revenue growth of 20.1% y-o-y to Rs. 850 crore (broadly in-line with our estimate of Rs. 862 crore), led by robust revenue growth of 24% y-o-y in domestic business (largely volume driven) and continued ramp-up in exports (up by 19% y-o-y). The company witnessed increased revenue in the domestic market owing to higher acreages across key products during Rabi season, which led to healthy demand off-take of the company products (increased volumes sold). Newly launched wheat herbicide 'Awkira' has been showing promising results. Gross margin remained at similar levels of 46.6%; however, operating margins improved by 94 BPS y-o-y to 21.9% (similar to our expectation of 21.9%) owing to economies of scale as other operating cost was down by 96 BPS to 15.7% of sales as compared to 16.6% during Q3FY2019. Healthy revenue growth and improvement in operating margin led to 25.5% growth in EBITDA at Rs. 187 crore. However, increased depreciation (up by 36.3% y-o-y) restricted PBT growth to 22.3% despite other income being higher by 25.7% y-o-y. Further, higher tax incidence of 28.7% in Q3FY2020 as against 22.8% in Q3FY2019 (owing to change in SEZ share to overall business) further restricted PAT growth to 13.0% at Rs. 121 crore (broadly in line with our estimate of Rs. 124 crore).

**Aggressively enhancing manufacturing capability owing to robust demand environment in exports:** Management highlighted that owing to strong demand from export markets (export order book remained stagnant at \$1.4 billion despite strong revenue growth implying a healthy order intake), the company is ramping up its capex programme. The multi-purpose plant in Jambusar facility (largely for backward integration and a new technology block) is slated to be commissioned in Q4FY2020. Three facilities are slated to be commissioned in FY2021E, one each in Q1FY2021, Q2FY2021 and Q3FY2021 or Q4FY2021. The company had outlined capex of Rs. 600 crore for FY2020 (Rs. 550 crore incurred till date) and Rs. 250 crore-300 crore for FY2021E. Management stated that asset-turnover ratio should be at 1.25x-1.75x for the new capacities; however, peak asset turnover should be reached in 12-18 months post commissioning at an utilisation level of 80-85%. The company is expected to fund the capex through internal accruals as operating cashflow generation is expected to remain robust; hence, reliance on external funding seems negligible.

### Highlights of Q3FY2020 Results concall

- ♦ **Focus on enhancing R&D capabilities continues:** As the number of enquires is increasing at a rapid pace, the pipeline in R&D activity is also increasing (recent development in China is one of the reasons for such surge in enquires). Scientist work on the technology shared by the customers in the CSM business along with working on the own proprietary molecules developed in-house. During the quarter, the company developed three new molecules in the CSM business, taking total molecules to 21. Management also stated that run-rate of 2-3 new product launches each year is expected to continue going forward as well.
- ♦ **H2 always better than H1:** Management highlighted that demand patterns are such that H2 performance is healthy as compared to H1 and sees no change this time as well.
- ♦ **Effective tax rate:** Management has guided for an effective tax rate of 25-26% for FY2020 and stated that it will evaluate the pros and cons of moving into the new tax rate regime for FY2021 as significant expansion plans are ongoing and it also has a facility in SEZ.
- ♦ **Lower dependence on China:** Management stated that the company has a lower dependence on China as revenue dependence is less than 10%. Further, over a period of time, the company has reduced vendor concentration to selected few as it diversified its raw-material sourcing from various suppliers situated in different geographies. Hence, management believes that outbreak of Corona virus in China is unlikely to have a significant impact on the company's overall performance.
- ♦ **Management retains its FY2020 guidance:** Though the accident at Jambusar facility is likely to have an adverse impact of Rs. 40 crore-50 crore on revenue during Q4FY2020, management believes that from the medium to long term perspective, it will not impact the business performance. Management has retained its FY2020E guidance of ~20% y-o-y improvement in performance, led by healthy order book, commissioning of additional capacity and contribution from newly launched brands.

- ♦ **Utilisation of surplus cash:** Healthy performance led to robust operating cash flow generation, which further strengthened the balance sheet. Hence, the company utilised the surplus cash in acquisition of balance stake in Isagro Asia along with capacity expansion at it Jambusar facility.
- ♦ **Amalgamation of Isagro Asia:** Post the acquisition of balance stake, Isagro Asia has become a wholly owned subsidiary of PI Industries and now it has been decided that it would merge Isagro Asia into PI Industries excluding the domestic distribution business, which will be transferred to Jivagro Limited.
- ♦ **Passed an enabling resolution to raise Rs. 2,000 crore:** To support the next phase of growth, the board approved an enabling resolution for raising funds upto Rs. 2,000 crore. Growth is expected to be led by either i) organic business growth through aggressive capacity expansion, ii) inorganic acquisition to acquire new and niche technological capabilities (either in domestic market or overseas), and iii) to diversify into adjacent verticals such as pharmaceuticals, hi-tech speciality chemicals, Nutraceuticals etc. or a combination of all.
- ♦ **Interim dividend:** The board has approved interim dividend of 300% on face value of Rs. 1 each, i.e. Rs 3/ share.

Results					Rs cr
Particulars	Q3FY20	Q3FY19	YoY (%)	Q2FY20	QoQ (%)
<b>Net Sales</b>	<b>850</b>	<b>708</b>	<b>20.1</b>	<b>907</b>	<b>(6.3)</b>
Material Cost	454	378	20.2	522	(13.1)
<b>Gross Profit</b>	<b>396</b>	<b>330</b>	<b>20.0</b>	<b>385</b>	<b>2.9</b>
Employee Expenses	76	64	19.9	73	4.9
Other Expenses	133	118	13.2	120	11.2
<b>EBITDA</b>	<b>187</b>	<b>149</b>	<b>25.5</b>	<b>193</b>	<b>(3.1)</b>
Other Income	19	15	25.7	11	75.2
Depreciation	32	23	36.3	32	0.6
Interest	4	2	153.3	3	52.0
<b>PBT</b>	<b>170</b>	<b>139</b>	<b>22.3</b>	<b>169</b>	<b>0.4</b>
Tax	49	32	54.1	46	5.6
<b>RPAT</b>	<b>121</b>	<b>107</b>	<b>13.0</b>	<b>123</b>	<b>(1.5)</b>
EPS (Rs)	8.8	7.8	13.0	8.9	(1.5)
%			YoY (BPS)		QoQ (BPS)
Gross profit margin	46.6	46.6	(3)	42.4	417
EBITDA margin	21.9	21.0	94	21.2	73
Net margin	14.3	15.2	(90)	13.6	70

Source: Company; Sharekhan Research

## Outlook


**Retains guidance of 20% revenue growth in FY2020:** Management highlighted that the demand pattern is such that the performance in H2 is healthy as compared to H1 and sees no change this time as well. Hence, it retains its FY2020E guidance of ~20% y-o-y improvement in performance led by healthy order book, commissioning of additional capacity and contribution from newly launched brands. The company had outlined a capex of Rs. 600 crore for FY2020 (Rs. 550 crore incurred till date) and Rs. 250 crore-300 crore for FY2021E. Three facilities are slated to be commissioned in FY2021E, one each in Q1FY2021, Q2FY2021 and Q3FY2021 or Q4FY2021.

## Valuation

### Aggressive expansion strategy to tap the robust and encouraging demand environment – Upgrade to Buy:

We expect revenue and earnings CAGR of 27.6% and 29.8%, respectively, during FY2019-FY2022E (Isagro numbers factored in from Q4FY2020). At the current market price, the stock is trading at 40.2x/28.9x/23.8x its FY2020E/FY2021E/FY2022E earnings. With industry-leading return ratios and a healthy balance sheet and strong earnings visibility, we expect the stock to continue to fetch premium valuations. We upgrade our rating on the stock to Buy with a revised PT of Rs. 1,750 per share owing to aggressive expansion strategy to tap the robust and encouraging demand environment.

One-year forward P/E (x) band – Trades at rich valuation, upside looks limited



Source: Sharekhan Research

## About company

Incorporated in 1947, PI Industries focuses on developing complex chemistry solutions in agri-sciences with an integrated approach. The company currently operates a strong infrastructure setup, consisting of three formulation facilities and nine multi-product plants under its three manufacturing facilities. These state-of-the-art facilities have integrated process development teams with in-house engineering capabilities. The company also maintains a strong research presence through its R&D facility at Udaipur and has a dedicated team of over 250 scientists and chemists.

## Investment theme

A strong CSM order book of \$1.4 billion at the end of Q3FY2020 provides healthy revenue visibility. Management foresees encouraging outlook for the CSM business as business sentiments improve globally for products, wherein the company operates. The company had outlined capex of Rs. 600 crore for FY2020 (Rs. 550 crore incurred till date) and Rs. 250 crore-300 crore for FY2021E. Three facilities are slated to be commissioned in FY2021E, one each in Q1FY2021, Q2FY2021 and Q3FY2021 or Q4FY2021.

## Key Risks

- ♦ Delay in commissioning of projects or execution of orders or deferral of orders by clients in the CSM business can affect revenue growth.
- ♦ Higher-than-normal time lag in passing on the increase in raw-material prices could affect margins.

## Additional Data

### Key management personnel

Narayan K. Seshadri	Non-Executive & Independent Chairperson
Dr. Raman Ramachandran	Managing Director & Chief Executive Officer
Mr. Mayank Singhal	Executive Director
Mr. Rajnish Sarna	Executive Director
Arvind Singhal	Non-Executive - Non Independent Director
Subhash Anand	Chief Financial Officer
Naresh Kapoor	Company Secretary & Compliance officer

Source: Company Website

### Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Jackson National Asset Management	5.11
2	ICICI Prudential Asset Management	4.47
3	SBI Funds Management Pvt Ltd	4.07
4	SBI LARGE MIDCAP FUND	4.03
5	Cartica Capital Ltd	3.50
6	UTI Asset Management Co Ltd	1.88
7	Franklin Templeton Mutual	1.81
8	DSP Investment Managers Pvt Ltd	1.44
9	Stichting Depository Apg Emerging Market	1.41
10	Vanguard Group Inc	1.35

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

# Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

**Disclaimer:** This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: [compliance@sharekhan.com](mailto:compliance@sharekhan.com);

For any queries or grievances kindly email [igc@sharekhan.com](mailto:igc@sharekhan.com) or contact: [myaccount@sharekhan.com](mailto:myaccount@sharekhan.com)

**Registered Office:** Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on [www.sharekhan.com](http://www.sharekhan.com); Investment in securities market are subject to market risks, read all the related documents carefully before investing.